Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and in vitro assessment via protein phosphorylation array

The efficacy and safety of lenvatinib (LEN) as a second/third-line treatment for unresectable hepatocellular carcinoma (HCC) after sorafenib (SOR) therapy remains unknown. We evaluated the outcomes of second/third-line LEN treatment, investigated the sensitivity of a SOR-resistant HCC cell line (PLC...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomonari, Tetsu, Sato, Yasushi, Tanaka, Hironori, Tanaka, Takahiro, Fujino, Yasuteru, Mitsui, Yasuhiro, Hirao, Akihiro, Taniguchi, Tatsuya, Okamoto, Koichi, Sogabe, Masahiro, Miyamoto, Hiroshi, Muguruma, Naoki, Kagiwada, Harumi, Kitazawa, Masashi, Fukui, Kazuhiko, Horimoto, Katsuhisa, Takayama, Tetsuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335665/
https://www.ncbi.nlm.nih.gov/pubmed/32655838
http://dx.doi.org/10.18632/oncotarget.27640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335665/
https://www.ncbi.nlm.nih.gov/pubmed/32655838
http://dx.doi.org/10.18632/oncotarget.27640

Ejemplares similares